Arbutus Biopharma Corp (ABUS) – key numbers that make it a Strong Buy For Now

Arbutus Biopharma Corp (NASDAQ: ABUS) is 10.40% higher on its value in year-to-date trading and has touched a low of $1.69 and a high of $3.14 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABUS stock was last observed hovering at around $2.54 in the last trading session, with the day’s gains setting it 0.22%.

Currently trading at $2.76, the stock is 15.53% and 19.87% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.81 million and changing 8.66% at the moment leaves the stock 26.02% off its SMA200. ABUS registered -2.47% loss for a year compared to 6-month gain of 33.98%. The firm has a 50-day simple moving average (SMA 50) of $14.86 and a 200-day simple moving average (SMA200) of -$4.50.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a 14.05% loss in the last 1 month and extending the period to 3 months gives it a 47.59%, and is 15.97% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.44% over the week and 4.93% over the month.

Profit margin for the company is -339.32%. Distance from 52-week low is 63.31% and -12.24% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.53%).

Arbutus Biopharma Corp quarterly earnings per share for the current quarter are estimated at -$0.12 with sales reaching $4.79M over the same period.The EPS is expected to grow by 5.22% this year, but quarterly earnings will post -46.70% year-over-year. Quarterly sales are estimated to shrink -23.30% in year-over-year returns.

Arbutus Biopharma Corp (ABUS) Top Institutional Holders

140 institutions hold shares in Arbutus Biopharma Corp (ABUS), with institutional investors hold 57.85% of the company’s shares. The shares outstanding are 157.46M, and float is at 125.20M with Short Float at 4.89%. Institutions hold 43.45% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 9.97 million shares valued at $22.93 million. The investor’s holdings represent 5.95% of the ABUS Shares outstanding. As of Jun 29, 2023, the second largest holder is Two Seas Capital Lp with 8.28 million shares valued at $19.05 million to account for 4.94% of the shares outstanding. The other top investors are Whitefort Capital Management, LP which holds 8.09 million shares representing 4.83% and valued at over $18.62 million, while Vanguard Group Inc holds 3.47% of the shares totaling 5.82 million with a market value of $13.38 million.

Arbutus Biopharma Corp (ABUS) Insider Activity

A total of 0 insider transactions have happened at Arbutus Biopharma Corp (ABUS) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by McElhaugh Michael J. ,the company’sInterim President & CEO. SEC filings show that McElhaugh Michael J. sold 10,164 shares of the company’s common stock on Feb 02 at a price of $2.31 per share for a total of $23504.0. Following the sale, the insider now owns 1.5 million shares.

Arbutus Biopharma Corp disclosed in a document filed with the SEC on Feb 02 that Sofia Michael J. (Chief Scientific Officer) sold a total of 9,982 shares of the company’s common stock. The trade occurred on Feb 02 and was made at $2.31 per share for $23083.0. Following the transaction, the insider now directly holds 1.49 million shares of the ABUS stock.

Still, SEC filings show that on Feb 02, HASTINGS DAVID C (Chief Financial Officer) disposed off 9,593 shares at an average price of $2.31 for $22184.0. The insider now directly holds 181,907 shares of Arbutus Biopharma Corp (ABUS).

Arbutus Biopharma Corp (ABUS): Who are the competitors?

The company’s main competitors (and peers) include Infinity Pharmaceuticals Inc. (INFIQ) that is trading -99.98% down over the past 12 months.